Regeneron Pharmaceuticals Faces Class Action Lawsuit
Analysis based on 7 articles · First reported Feb 03, 2025 · Last updated Mar 03, 2025
The market is impacted by the potential financial and reputational damage to Regeneron Pharmaceuticals due to the class action lawsuit and allegations of violating the False Claims Act of 1863. Investors who purchased shares during the class period may incur losses, leading to a negative sentiment for Regeneron Pharmaceuticals' stock.
The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit. The lawsuit alleges that Regeneron Pharmaceuticals made materially false and misleading statements by failing to disclose that it paid credit card fees to distributors for its product Aflibercept. These payments allegedly subsidized customer prices, provided a competitive advantage, and misleadingly boosted reported Aflibercept sales. Furthermore, by not reporting these payments as price concessions, Regeneron Pharmaceuticals is accused of overstating the Average Sales Price (ASP) to federal agencies, thereby violating the False Claims Act of 1863. Shareholders who purchased shares between November 2, 2023, and October 30, 2024, are encouraged to contact the firm, with a deadline of March 10, 2025, to seek lead plaintiff appointment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard